Current and emerging cell culture manufacturing technologies for influenza vaccines

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Milián, Ernest ^a   Kamen, Amine A ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

CELL CULTURE; DRUG FORMULATION; HUMAN; INFLUENZA VIRUS; INSECT CELL CULTURE; MAMMAL CELL; NONHUMAN; PANDEMIC; REVIEW; SEASONAL INFLUENZA; VACCINE PRODUCTION; CULTURE TECHNIQUE; DRUG EFFECTS; IMMUNOLOGY; INFLUENZA, HUMAN; ORTHOMYXOVIRIDAE; PATHOGENICITY; VACCINATION; VIROLOGY;

HEXAPODA; MAMMALIA; ORTHOMYXOVIRIDAE;

CELL CULTURE TECHNIQUES; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; ORTHOMYXOVIRIDAE; VACCINATION;

EID: 84925321762     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/504831     Document Type: Review

References (94)

1. P. Palese, "The genes of influenza virus, " Cell, vol. 10, no. 1, pp. 1-10, 1977.
2. W. Chen, P. A. Calvo, D. Malide et al., "A novel influenza A virus mitochondrial protein that induces cell death, " Nature Medicine, vol. 7, no. 12, pp. 1306-1312, 2001.
3. H. M. Wise, A. Foeglein, J. Sun et al., "A complicatedmessage: identification of a novel PB1-related protein translated from influenza A virus segment 2 mRNA, " Journal of Virology, vol. 83, no. 16, pp. 8021-8031, 2009.
4. B. W. Jagger, H. M. Wise, J. C. Kash et al., "An overlapping protein-coding region in influenzaAvirus segment 3modulates the host response, " Science, vol. 337, no. 6091, pp. 199-204, 2012.
5. Y. Muramoto, T. Noda, E. Kawakami, R. Akkina, and Y. Kawaokaa, "Identification of novel influenza A virus proteins translated from PA mRNA, " Journal of Virology, vol. 87, no. 5, pp. 2455-2462, 2013.
6. S. Tong, Y. Li, P. Rivailler et al., "A distinct lineage of influenza A virus frombats, " Proceedings of theNational Academy of Sciences of the United States of America, vol. 109, no. 11, pp. 4269-4274, 2012.
7. M. Yamashita, M. Krystal, W. M. Fitch, and P. Palese, "Influenza B virus evolution: co-circulating lineages and comparison of evolutionary pattern with those of influenza A and C viruses, " Virology, vol. 163, no. 1, pp. 112-122, 1988.
8. A. J. Caton, G. G. Brownlee, J. W. Yewdell, and W. Gerhard, "The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype), " Cell, vol. 31, no. 2, pp. 417-427, 1982.
9. A. J. Hay, V. Gregory, A. R. Douglas, and P. L. Yi, "The evolution of human influenza viruses, " Philosophical Transactions of the Royal Society B: Biological Sciences, vol. 356, no. 1416, pp. 1861-1870, 2001.
10. J. K. Taubenberger and J. C. Kash, "Influenza virus evolution, host adaptation, and pandemic formation, " Cell Host and Microbe, vol. 7, no. 6, pp. 440-451, 2010.
11. P. D. Minor, O. G. Engelhardt, J. M. Wood et al., "Current challenges in implementing cell-derived influenza vaccines: implications for production and regulation, July 2007, NIBSC, Potters Bar, UK, " Vaccine, vol. 27, no. 22, pp. 2907-2913, 2009.
12. R. Verma, P. Khanna, and S. Chawla, "Influenza vaccine: an effective preventive vaccine for developing countries, " Human Vaccines and Immunotherapeutics, vol. 8, no. 5, pp. 675-678, 2012.
13. A. H. Ellebedy and R. J. Webby, "Influenza vaccines, " Vaccine, vol. 27, supplement 4, pp. D65-D68, 2009.
14. D. P. Greenberg, C. A. Robertson, M. J. Noss, M. M. Blatter, R. Biedenbender, and M. D. Decker, "Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults, " Vaccine, vol. 31, no. 5, pp. 770-776, 2013.
15. K. Stöhr, "Influenza vaccine production, " in Textbook of Influenza, pp. 352-370, JohnWiley and Sons, 2013
16. FDA full prescribing information FluMist, http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM123743.pdf.
17. R. A. Webster, R. G. Monto, A. S. Braciale, and T. J. Lamb, Textbook of Influenza, JohnWiley and Sons, Oxford, UK, 2013.
18. J. B. Ulmer, U. Valley, and R. Rappuoli, "Vaccine manufacturing: challenges and solutions, " Nature Biotechnology, vol. 24, no. 11, pp. 1377-1383, 2006.
19. G. I. Alexandrova, G. N. Budilovsky, T. A. Koval et al., "Study of live recombinant cold-adapted influenza bivalent vaccine of type A for use in children: an epidemiological control trial, " Vaccine, vol. 4, no. 2, pp. 114-118, 1986.
20. Y. Z. Ghendon, F. I. Polezhaev, K. V. Lisovskaya, T. E. Medvedeva, G. I. Alexandrova, and A. I. Klimov, "Recombinant cold-adapted attenuated influenza A vaccines for use in children: molecular genetic analysis of the cold-adapted donor and recombinants, " Infection and Immunity, vol. 44, no. 3, pp. 730-733, 1984.
21. J. Partridge and M. P. Kieny, "Global production capacity of seasonal influenza vaccine in 2011, " Vaccine, vol. 31, no. 5, pp. 728-731, 2013.
22. S.-S. Wong and R. J. Webby, "Traditional and new influenza vaccines, " ClinicalMicrobiology Reviews, vol. 26, no. 3, pp. 476-492, 2013.
23. P. R. Dormitzer, T. F. Tsai, and G. Del Giudice, "New technologies for influenza vaccines, " Human Vaccines and Immunotherapeutics, vol. 8, no. 1, pp. 45-58, 2012.
24. M. Hilleringmann, B. Jobst, and B. C. Baudner, "Influenza cellculture vaccine production, " in Molecular Vaccines, M. Giese, Ed., pp. 823-837, Springer International Publishing, Cham, Switzerland, 2014.
25. C. T. Hardy, S. A. Young, R. G. Webster, C. W. Naeve, and R. J. Owens, "Egg fluids and cells of the chorioallantoic membrane of embryonated chicken eggs can select different variants of influenza A (H3N2) viruses, " Virology, vol. 211, no. 1, pp. 302-306, 1995.
26. J. S. Robertson, J. S. Bootman, R. Newman et al., "Structural changes in the haemagglutinin which accompany egg adaptation of an influenza A(H1N1) virus, " Virology, vol. 160, no. 1, pp. 31-37, 1987.
27. J. S. Robertson, P. Cook, A.-M. Attwell, and S. P. Williams, "Replicative advantage in tissue culture of egg-adapted influenza virus over tissue-culture derived virus: implications for vaccine manufacture, " Vaccine, vol. 13, no. 16, pp. 1583-1588, 1995.
28. K. S. Reisinger, S. L. Block, A. Izu, N. Groth, and S. J. Holmes, "Subunit Influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety, reactogenicity, andimmunogenicity, " Journal of InfectiousDiseases, vol. 200, no. 6, pp. 849-857, 2009.
29. N. Bardiya and J. H. Bae, "Influenza vaccines: recent advances in production technologies, " Applied Microbiology and Biotechnology, vol. 67, no. 3, pp. 299-305, 2005.
30. J. M. Katz, C. W. Naeve, and R. G. Webster, "Host cell-mediated variation in H3N2 influenza viruses, " Virology, vol. 156, no. 2, pp. 386-395, 1987.
31. J. M. Katz and R. G. Webster, "Efficacy of inactivated influenza A virus (H3N2) vaccines grown in mammalian cells or embryonated eggs, " Journal of Infectious Diseases, vol. 160, no. 2, pp. 191-198, 1989.
32. W. J. Meyer, J. M. Wood, D. Major, J. S. Robertson, R. G. Webster, and J. M. Katz, "Influence of host cell-mediated variation on the international surveillance of influenza A (H3N2) viruses, " Virology, vol. 196, no. 1, pp. 130-137, 1993
33. WHO, Process of Influenza Vaccine Virus Selection and Development, World Health Organization, 2007.
34. E. D. Kilbourne, "Future influenza vaccines and the use of genetic recombinants, " Bulletin of the World Health Organization, vol. 41, no. 3, pp. 643-645, 1969.
35. E. Fodor, L. Devenish, O. G. Engelhardt, P. Palese, G. G. Brownlee, and A. García-Sastre, "Rescue of influenza A virus from recombinant DNA, " Journal of Virology, vol. 73, no. 11, pp. 9679-9682, 1999.
36. G. Neumann, T. Watanabe, H. Ito et al., "Generation of influenza A viruses entirely from cloned cDNAs, " Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 16, pp. 9345-9350, 1999.
37. E. Hoffmann, G. Neumann, Y. Kawaoka, G. Hobom, and R. G. Webster, "A DNA transfection system for generation of influenza A virus from eight plasmids, " Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 11, pp. 6108-6113, 2000.
38. O. G. Engelhardt, "Many ways to make an influenza virus-review of influenza virus reverse genetics methods, " Influenza and other Respiratory Viruses, vol. 7, no. 3, pp. 249-256, 2013.
39. S. Ye, J. G. Evans, and J. Stambas, "Influenza reverse genetics: dissecting immunity and pathogenesis, " Expert Reviews in Molecular Medicine, vol. 16, article e2, 2014.
40. R. J. Webby, D. R. Perez, J. S. Coleman et al., "Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines, " The Lancet, vol. 363, no. 9415, pp. 1099-1103, 2004.
41. C. Nicolson, D. Major, J. M. Wood, and J. S. Robertson, "Generation of influenza vaccine viruses onVero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system, " Vaccine, vol. 23, no. 22, pp. 2943-2952, 2005
42. WHO, Manual for the Laboratory Diagnosis and Virological Surveillance of Influenza, World Health Organization, Geneva, Switzerland, 2011.
43. P. Dormitzer, "Cell culture-derived influenza vaccines, " in Influenza Vaccines for the Future, R. Rappuoli and G. Del Giudice, Eds., pp. 293-312, Springer, Basel, Switzerland, 2011.
44. C. Gerdil, "The annual production cycle for influenza vaccine, " Vaccine, vol. 21, no. 16, pp. 1776-1779, 2003.
45. WHO, "Recommendations for the production and control of influenza vaccine (inactivated), " WHO Tech. Rep. Series 927, 2005.
46. Y. Genzel and U. Reichl, "Continuous cell lines as a production system for influenza vaccines, " Expert Review of Vaccines, vol. 8, no. 12, pp. 1681-1692, 2009.
47. A. LeRu, D. Jacob, J. Transfiguracion, S. Ansorge, O. Henry, and A. A. Kamen, "Scalable production of influenza virus in HEK-293 cells for efficient vaccine manufacturing, " Vaccine, vol. 28, no. 21, pp. 3661-3671, 2010.
48. G. F. Rimmelzwaan, M. Baars, E. C. J. Claas, and A. D. M. E. Osterhaus, "Comparison of RNA hybridization, hemagglutination assay, titration of infectious virus and immunofluorescence as methods for monitoring influenza virus replication in vitro, " Journal of Virological Methods, vol. 74, no. 1, pp. 57-66, 1998.
49. J. T. M. Voeten, R. Brands, A. M. Palache et al., "Characterization of high-growth reassortant influenza A viruses generated in MDCK cells cultured in serum-free medium, " Vaccine, vol. 17, no. 15-16, pp. 1942-1950, 1999.
50. M. G. Pau, C. Ophorst, M. H. Koldijk, G. Schouten, M. Mehtali, and F. Uytdehaag, "The human cell line PER. C6 provides a new manufacturing systemfor the production of influenza vaccines, " Vaccine, vol. 19, no. 17-19, pp. 2716-2721, 2001.
51. O. Kistner, P. N. Barrett, W. Mundt, M. Reiter, S. Schober-Bendixen, and F. Dorner, "Development of a mammalian cell (Vero) derived candidate influenza virus vaccine, " Vaccine, vol. 16, no. 9-10, pp. 960-968, 1998.
52. R. Youil, Q. Su, T. J. Toner et al., "Comparative study of influenza virus replication in Vero and MDCK cell lines, " Journal of Virological Methods, vol. 120, no. 1, pp. 23-31, 2004.
53. A. M. Palache, R. Brands, and G. J. M. van Scharrenburg, "Immunogenicity and reactogenicity of influenza subunit vaccines produced in MDCK cells or fertilized chicken eggs, " Journal of Infectious Diseases, vol. 176, supplement 1, pp. S20-S23, 1997.
54. A. Doroshenko and S. A. Halperin, "Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines), " Expert Review of Vaccines, vol. 8, no. 6, pp. 679-688, 2009.
55. J. Luo, "Egg-independent influenza vaccine: making great strides forward, " Journal of Applied Virology, vol. 2, no. 2, pp. 1-4, 2013.
56. A. Groener and J. Vorlop, "Animal cells and processes for the replication of influenza viruses, " 1997, http://www.google.com/patents/WO1997037000A1cl=en.
57. T. F. Tsai and H. Trusheim, "Making influenza virus vaccines without using eggs, " 2010, http://www.google.com/patents/US20100010199.
58. European Medicines, Questions and Answers on the Review of Preflucel and Associated Genes, 2012.
59. P. N. Barrett, W. Mundt, O. Kistner, and M. K. Howard, "Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines, " Expert Review of Vaccines, vol. 8, no. 5, pp. 607-618, 2009.
60. P. N. Barrett, G. Berezuk, S. Fritsch et al., "Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial, " The Lancet, vol. 377, no. 9767, pp. 751-759, 2011.
61. H. J. Ehrlich, G. Berezuk, S. Fritsch et al., "Clinical development of a Vero cell culture-derived seasonal influenza vaccine, " Vaccine, vol. 30, no. 29, pp. 4377-4386, 2012.
62. H. J. Ehrlich, J. Singer, G. Berezuk et al., "A cell culturederived influenza vaccine provides consistent protection against infection and reduces the duration and severity of disease in infected individuals, " Clinical Infectious Diseases, vol. 54, no. 7, pp. 946-954, 2012.
63. T. Vicente, A. Roldão, C. Peixoto, M. J. T. Carrondo, and P. M. Alves, "Large-scale production and purification of VLPbased vaccines, " Journal of Invertebrate Pathology, vol. 107, supplement, pp. S42-S48, 2011.
64. J. C. King Jr., M. M. Cox, K. Reisinger, J. Hedrick, I. Graham, and P. Patriarca, "Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirusexpressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59months, " Vaccine, vol. 27, no. 47, pp. 6589-6594, 2009.
65. R. Baxter, P. A. Patriarca, K. Ensor, R. Izikson, K. L. Goldenthal, and M. M. Cox, "Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirusexpressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age, " Vaccine, vol. 29, no. 12, pp. 2272-2278, 2011.
66. M. M. J. Cox and J. R. Hollister, "FluBlok, a next generation influenza vaccine manufactured in insect cells, " Biologicals, vol. 37, no. 3, pp. 182-189, 2009.
67. J. O. Josefsberg and B. Buckland, "Vaccine process technology, " Biotechnology and Bioengineering, vol. 109, no. 6, pp. 1443-1460, 2012.
68. M. M. J. Cox and Y. Hashimoto, "A fast track influenza virus vaccine produced in insect cells, " Journal of Invertebrate Pathology, vol. 107, no. supplement, pp. S31-S41, 2011.
69. A. Shaw, "New technologies for new influenza vaccines, " Vaccine, vol. 30, no. 33, pp. 4927-4933, 2012.
70. Y. Z. Ghendon, S. G. Markushin, I. I. Akopova et al., "Development of cell culture (MDCK) live cold-adapted (CA) attenuated influenza vaccine, " Vaccine, vol. 23, no. 38, pp. 4678-4684, 2005.
71. J. Liu, X. Shi, R. Schwartz, and G. Kemble, "Use of MDCK cells for production of live attenuated influenza vaccine, " Vaccine, vol. 27, no. 46, pp. 6460-6463, 2009.
72. J. Romanova, D. Katinger, B. Ferko et al., "Live cold-adapted influenza A vaccine produced in Vero cell line, " Virus Research, vol. 103, no. 1-2, pp. 187-193, 2004.
73. Z. Wei, M. Mcevoy, V. Razinkov et al., "Biophysical characterization of influenza virus subpopulations using field flow fractionation and multiangle light scattering: correlation of particle counts, size distribution and infectivity, " Journal of Virological Methods, vol. 144, no. 1-2, pp. 122-132, 2007.
74. J. A. Tree, C. Richardson, A. R. Fooks, J. C. Clegg, and D. Looby, "Comparison of large-scale mammalian cell culture systems with egg culture for the production of influenza virus A vaccine strains, " Vaccine, vol. 19, no. 25-26, pp. 3444-3450, 2001.
75. M. George, M. Farooq, T. Dang, B. Cortes, J. Liu, and L. Maranga, "Production of cell culture (MDCK) derived live attenuated influenza vaccine (LAIV) in a fully disposable platform process, " Biotechnology and Bioengineering, vol. 106, no. 6, pp. 906-917, 2010.
76. J. Steel, A. C. Lowen, L. Pena et al., "Live attenuated influenza viruses containing NS1 truncations as vaccine candidates against H5N1 highly pathogenic avian influenza, " Journal of Virology, vol. 83, no. 4, pp. 1742-1753, 2009.
77. B. Zhou, Y. Li, J. A. Belser et al., "NS-based live attenuated H1N1 pandemic vaccines protect mice and ferrets, " Vaccine, vol. 28, no. 50, pp. 8015-8025, 2010.
78. H. Akarsu, K. Iwatsuki-Horimoto, T. Noda et al., "Structurebased design of NS2 mutants for attenuated influenza A virus vaccines, " Virus Research, vol. 155, no. 1, pp. 240-248, 2011.
79. J. Romanova, B. M. Krenn, M. Wolschek et al., "Preclinical evaluation of a replication-deficient intranasal NS1 H5N1 influenza vaccine, " PLoS ONE, vol. 4, no. 6, Article ID e5984, 2009.
80. V. Wacheck, A. Egorov, F. Groiss et al., "Anovel type of influenza vaccine: safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist NS1, " Journal of Infectious Diseases, vol. 201, no. 3, pp. 354-362, 2010.
81. C. López-Macías, E. Ferat-Osorio, A. Tenorio-Calvo et al., "Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico, " Vaccine, vol. 29, no. 44, pp. 7826-7834, 2011.
82. S. V. Vemula and S. K. Mittal, "Production of adenovirus vectors and their use as a delivery system for influenza vaccines, " Expert Opinion on Biological Therapy, vol. 10, no. 10, pp. 1469-1487, 2010.
83. K. R. Van Kampen, Z. Shi, P. Gao et al., "Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans, " Vaccine, vol. 23, no. 8, pp. 1029-1036, 2005.
84. D. E.-C. Tang, R. S. Jennelle, Z. Shi et al., "Overexpression of adenovirus-encoded transgenes from the cytomegalovirus immediate early promoter in irradiated tumor cells, " Human GeneTherapy, vol. 8, no. 17, pp. 2117-2124, 1997.
85. W. Peters, J. R. Brandl, J. D. Lindbloom et al., "Oral administration of an adenovirus vector encoding both an avian influenza A hemagglutinin and a TLR3 ligand induces antigen specific granzyme B and IFN-T cell responses in humans, " Vaccine, vol. 31, no. 13, pp. 1752-1758, 2013.
86. M. Gurwith, M. Lock, E. M. Taylor et al., "Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a Randomised, double-blind, placebocontrolled, phase 1 study, " The Lancet Infectious Diseases, vol. 13, no. 3, pp. 238-250, 2013.
87. R. D. Antrobus, L. Coughlan, T. K. Berthoud et al., "Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved influenza A antigens, " MolecularTherapy, vol. 22, no. 3, pp. 668-674, 2013.
88. S. V. Vemula, Y. S. Ahi, A.-M. Swaim et al., "Broadly protective adenovirus-based multivalent vaccines against highly pathogenic avian influenza viruses for pandemic preparedness, " PLoS ONE, vol. 8, no. 4, Article ID e62496, 2013.
89. J. Zhang, E. B. Tarbet, T. Feng, Z. Shi, K. R. van Kampen, and D.-C. C. Tang, "Adenovirus-vectored drug-vaccine duo as a rapid-response tool for conferring seamless protection against influenza, " PLoS ONE, vol. 6, no. 7, Article ID e22605, 2011.
90. J. Alexander, S. Ward, J. Mendy et al., "Pre-clinical evaluation of a replication-competent recombinant adenovirus serotype 4 vaccine expressing influenza H5 hemagglutinin, " PLoS ONE, vol. 7, no. 2, Article ID e31177, 2012.
91. M. A. Croyle, D. J. Anderson, B. J. Roessler, and G. L. Amidon, "Development of a highly efficient purification process for recombinant adenoviral vectors for oral gene delivery, " Pharmaceutical Development and Technology, vol. 3, no. 3, pp. 365-372, 1998.
92. D. C. C. Tang, J. Zhang, H. Toro, Z. Shi, and K. R. VanKampen, "Adenovirus as a carrier for the development of influenza virusfree avian influenza vaccines, " Expert Review of Vaccines, vol. 8, no. 4, pp. 469-481, 2009.
93. C. F. Shen, S. Lanthier, D. Jacob et al., "Process optimization and scale-up for production of rabies vaccine live adenovirus vector (AdRG1. 3), " Vaccine, vol. 30, no. 2, pp. 300-306, 2012.
94. A. Kamen and O. Henry, "Development and optimization of an adenovirus production process, " Journal of Gene Medicine, vol. 6, supplement 1, pp. S184-S192, 2004.